Thalidomide is drug of choice for …………. , if two courses of glucocorticoids fail.
First, I need to recall what conditions thalidomide is used for. Thalidomide is known for its anti-inflammatory and immunomodulatory properties. It's used in some autoimmune conditions. The question mentions glucocorticoids failing, so probably an autoimmune disease where steroids are first-line.
Glucocorticoids like prednisone are often used for conditions like Behçet's disease, lupus, or maybe certain types of vasculitis. But thalidomide is specifically associated with Behçet's disease, especially for oral and genital ulcers. If steroids aren't working, thalidomide might be the next step.
Wait, another possibility is leprosy reactions. Thalidomide is used for erythema nodosum leprosum. But the question says "two courses of glucocorticoids fail"—glucocorticoids are used in leprosy reactions too, but maybe thalidomide is preferred over steroids in some cases. However, I think the more common indication for thalidomide after steroids in Behçet's is more likely here.
Let me check standard guidelines. Thalidomide is considered a second-line treatment for Behçet's syndrome, especially for mucocutaneous manifestations, when first-line therapies like glucocorticoids and immunosuppressants (like azathioprine) have failed. So the correct answer here is Behçet's disease.
Now, the options A-D are missing, but the correct answer is Behçet's. The other options would be distractors like other autoimmune diseases. For example, options might include lupus, vasculitis, or others. I need to explain why each wrong option is incorrect.
Clinical pearl: Remember that thalidomide's use in Behçet's is for its anti-TNF properties, and it's effective for mucocutaneous ulcers. Also, it has teratogenic effects, so pregnancy is contraindicated.
So putting it all together: The core concept is thalidomide's role in Behçet's after glucocorticoids. The correct answer is Behçet's disease. The wrong options would be other conditions where thalidomide isn't the standard. Clinical pearl about teratogenicity and indication.
**Core Concept**
Thalidomide is an **immunomodulatory drug** with **anti-TNF-α** activity, primarily used for **Behçet’s syndrome** when **glucocorticoids fail**. Its mechanism involves suppressing pro-inflammatory cytokines and modulating T-cell responses.
**Why the Correct Answer is Right**
Thalidomide is a **second-line treatment** for **Behçet’s syndrome**, particularly for **recurrent oral/genital ulcers** and uveitis, after glucocorticoids and conventional immunosuppressants (e.g., azathioprine) have failed. Its efficacy stems from **inhibiting TNF-α**, reducing inflammation, and promoting remission. Clinical guidelines